Tirzepatide for Sleep Apnea: FDA-Approved Treatment That Also Causes Weight Loss

In a first for medicine, the FDA has approved a drug specifically for the treatment of obstructive sleep apnea — and it is the same GLP-1 medication already transforming obesity care. Zepbound (tirzepatide), made by Eli Lilly, received FDA approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity in 2024. The pivotal SURMOUNT-OSA trials showed AHI reductions of 55–63%, and nearly half of patients achieved enough improvement to potentially discontinue CPAP. Here is everything you need to know about this landmark approval, the trial data behind it, and how to access compounded tirzepatide affordably.

What Is Obstructive Sleep Apnea and Why Does Weight Matter?

Obstructive sleep apnea affects an estimated 30 million Americans, though many cases remain undiagnosed. OSA occurs when the muscles and soft tissue surrounding the upper airway relax during sleep, causing the airway to narrow or collapse repeatedly throughout the night. Each collapse — called an apnea or hypopnea event — briefly starves the body of oxygen, triggering a micro-arousal that fragments sleep without the person fully waking.

Severity is measured using the apnea-hypopnea index (AHI), which counts the number of these events per hour of sleep. Mild OSA is 5–14 events per hour; moderate is 15–29; severe is 30 or more. People with severe untreated OSA can experience hundreds of oxygen desaturation events per night, with consequences ranging from daytime sleepiness and cognitive impairment to dramatically elevated risk of hypertension, atrial fibrillation, stroke, and type 2 diabetes.

Excess body weight — particularly fat deposits in the neck, tongue, and soft palate — is the single largest modifiable risk factor for OSA. Even modest weight loss of 5–10% of body weight can reduce OSA severity meaningfully. Conversely, weight gain is the most common reason for OSA to worsen or recur after treatment. This biological relationship is why researchers suspected that GLP-1 medications, with their unprecedented ability to produce 15–25% body weight loss, might profoundly change OSA outcomes.

The FDA Approval: A Historic First

On June 21, 2024, the FDA approved Zepbound (tirzepatide) injection for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This was the first time any drug had ever received an FDA indication specifically for OSA — a condition that has been managed almost exclusively through devices (CPAP, BiPAP, oral appliances) or surgery for decades.

The approval added a second indication to Zepbound, which had already been approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. This means patients with obesity and OSA may qualify for Zepbound coverage under either — or both — indications, depending on their insurer's criteria.

The FDA review was based on data from the SURMOUNT-OSA clinical trial program, a pair of phase 3 randomized controlled trials that together enrolled over 450 patients across the United States and globally. The results were published in the New England Journal of Medicine and presented at the American Thoracic Society International Conference.

SURMOUNT-OSA: What the Trial Data Showed

Trial Design

SURMOUNT-OSA consisted of two parallel randomized controlled trials running 52 weeks each. Both enrolled adults with a BMI of 30 or higher and moderate-to-severe OSA (AHI ≥ 15 events per hour). Trial 1 enrolled patients who were not using CPAP therapy, while Trial 2 enrolled patients who were continuing to use CPAP throughout the study. Patients were randomized to once-weekly subcutaneous tirzepatide (titrated to 10 mg or 15 mg based on tolerability) or matching placebo. The primary endpoint was change in AHI from baseline.

Key Efficacy Results

• Trial 1 (no CPAP): Tirzepatide reduced AHI by a mean of 29.3 events per hour versus 5.3 events per hour for placebo — a statistically and clinically significant difference. This represented a roughly 55% relative reduction.
• Trial 2 (CPAP users): Tirzepatide reduced AHI by a mean of 25.3 events per hour versus 5.5 events per hour for placebo — approximately a 63% relative reduction from a higher baseline.
• OSA resolution: In Trial 1, 46% of tirzepatide patients achieved AHI below 5 events per hour (the threshold below which OSA is no longer diagnosed) by week 52. In the placebo group, only 8% reached this threshold.
• Remission rate: Across both trials, approximately 42–48% of tirzepatide patients achieved AHI levels at or below the threshold for clinical significance.
• Weight loss: Tirzepatide patients lost a mean of 18–20% of their body weight over 52 weeks, compared to 1–3% for placebo patients.

Secondary Outcomes

Beyond the primary AHI endpoint, tirzepatide-treated patients showed significant improvements across multiple clinically important secondary outcomes:

• Hypoxic burden (total time with oxygen saturation below 90%) reduced by 60–70%
• Epworth Sleepiness Scale scores improved by 4–5 points (clinically meaningful)
• Patient-reported sleep quality on PROMIS Sleep Disturbance improved substantially
• Systolic blood pressure reduced by approximately 8 mmHg versus placebo
• High-sensitivity CRP (inflammatory marker) reduced significantly
• Waist circumference decreased by 15–18 cm on average

These secondary benefits are important because OSA is not just a sleep quality problem — it is a major cardiovascular risk factor. Improvements in blood pressure, inflammation, and oxygenation suggest that tirzepatide's benefits extend beyond AHI alone.

How Tirzepatide Treats Sleep Apnea

Primary Mechanism: Airway Fat Reduction

The dominant mechanism by which tirzepatide improves OSA is substantial fat loss from the upper airway and surrounding anatomy. Fat deposits in the neck, tongue base, soft palate, and lateral pharyngeal walls are major contributors to airway narrowing during sleep. As these deposits shrink through weight loss, the airway becomes less susceptible to collapse. This is confirmed by imaging studies showing measurable reductions in tongue and neck fat volume in patients on GLP-1 therapy.

Abdominal and Chest Fat Reduction

Reduced visceral and subcutaneous abdominal fat also improves respiratory mechanics during sleep. Excess abdominal weight presses upward on the diaphragm when lying supine, reducing functional residual capacity and increasing the tendency for airway collapse. Weight loss from tirzepatide relieves this mechanical load, particularly benefiting patients whose OSA is most severe in the supine position.

Potential Direct GLP-1 Effects

Emerging research suggests GLP-1 receptor agonists may have effects on upper airway musculature and inflammation independent of weight loss. GLP-1 receptors are expressed in the central nervous system regions that control upper airway muscle tone during sleep, and animal studies have demonstrated direct effects on genioglossus muscle activity. Whether these contribute meaningfully to tirzepatide's clinical OSA benefit in humans is under active investigation.

Tirzepatide vs CPAP: Comparing the Two Standards

CPAP remains the most immediately effective treatment for OSA — it reduces AHI by 90–95% from the first night of proper use. By contrast, tirzepatide takes 6–12 months to produce significant AHI improvements and still leaves roughly half of patients with residual OSA that may require continued CPAP. So why is this FDA approval significant?

The answer lies in what CPAP cannot do. CPAP is a lifelong symptomatic therapy that treats the nightly consequence of OSA but does nothing to address weight, cardiovascular risk, metabolic health, or any other downstream consequence. CPAP adherence is notoriously poor — 30–50% of patients abandon it within the first year due to discomfort, claustrophobia, and travel burden. A patient who cannot tolerate CPAP has, until now, had no pharmacological alternative.

For more on how these two approaches compare head to head, see our full guide at CPAP vs GLP-1: Can Weight Loss Replace Your Sleep Machine?.

The two treatments are not mutually exclusive. The SURMOUNT-OSA Trial 2 results showed that tirzepatide produced significant AHI reductions even in patients continuing CPAP — meaning patients can use both simultaneously. Many sleep specialists now recommend starting GLP-1 therapy alongside CPAP, with a plan to reassess CPAP needs after a repeat sleep study once target weight loss is achieved.

Who Qualifies for Tirzepatide for Sleep Apnea?

FDA-Approved Patient Profile

The FDA approval for OSA specifically covers:

• Adults aged 18 and older
• Obesity (BMI ≥ 30 kg/m²)
• Moderate-to-severe obstructive sleep apnea (AHI ≥ 15 events per hour on sleep study)

Note that a prior sleep study (polysomnography or home sleep apnea test) documenting OSA is required to qualify under this specific indication. Patients who have never had a sleep study but suspect they have OSA should discuss evaluation with their provider.

Broader Qualifying Criteria

Many patients will also qualify for tirzepatide under its weight management indication, which requires a BMI ≥ 30 or a BMI ≥ 27 with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia). OSA itself counts as such a comorbidity. This creates multiple pathways to coverage, and providers can prescribe based on whichever indication best fits the patient's clinical picture and insurance requirements.

The Dual Benefit: Treating OSA AND Achieving Weight Loss

One of the most compelling aspects of tirzepatide for OSA is that treating the sleep disorder simultaneously produces benefits that extend far beyond sleep. Patients in the SURMOUNT-OSA trials lost an average of 18–20% of their body weight — a level of weight loss previously achievable only through bariatric surgery.

This weight loss is not a side effect of OSA treatment — it is the mechanism. But it carries benefits entirely independent of sleep apnea: reduced risk of type 2 diabetes, lower blood pressure, improved lipid profiles, decreased joint pain, improved fertility, and emerging evidence of reduced risk of certain cancers. Patients who start tirzepatide for OSA are, in effect, treating multiple chronic conditions simultaneously with a single weekly injection.

For a comprehensive look at what GLP-1 medications can do beyond weight loss, see our guide to the best GLP-1 medications in 2026.

What Happens After Stopping Tirzepatide?

This is a critical consideration. The SURMOUNT-OSA trials ran 52 weeks, and longer-term extension data and discontinuation studies confirm a pattern seen across all GLP-1 weight loss research: weight returns substantially when the medication is stopped. Studies of tirzepatide and semaglutide show that patients regain approximately two-thirds of lost weight within 12 months of discontinuation.

For OSA, this means that remission achieved on tirzepatide is dependent on maintaining the weight loss, which in turn depends on continuing the medication. Patients who achieve OSA resolution and then stop tirzepatide should plan to resume CPAP monitoring and consider a repeat sleep study within 6–12 months of discontinuation.

This does not diminish the value of the treatment — many conditions requiring long-term medication management (hypertension, diabetes, depression) are similarly dependent on continued therapy. But it does mean that patients and providers should frame tirzepatide for OSA as a long-term commitment, not a temporary course of treatment.

Side Effects and Considerations

The safety profile of tirzepatide for OSA is consistent with its established profile for weight management. The most common adverse effects are gastrointestinal:

• Nausea (40–45% of patients, typically most pronounced in the first 4–8 weeks)
• Diarrhea (20–25%)
• Constipation (15–20%)
• Vomiting (10–15%)
• Decreased appetite (expected therapeutic effect)

GI side effects are almost always dose-dependent and can be minimized by following the standard titration schedule (starting at 2.5 mg weekly and increasing by 2.5 mg increments no faster than every 4 weeks). Most patients develop tolerance after the first dose escalation. For tips on reducing GI side effects, see our guide on managing GLP-1 side effects.

Less common but important potential side effects include pancreatitis (rare), gallbladder disease, heart rate increase, and injection-site reactions. Tirzepatide carries an FDA black box warning for thyroid C-cell tumors based on rodent data, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

How to Get Tirzepatide for Sleep Apnea

Brand-Name Zepbound

The brand-name version, Zepbound, is available through specialty pharmacies with a valid prescription. List price is approximately $1,000–$1,400 per month, though manufacturer savings programs and insurance coverage can substantially reduce this. With the OSA indication, some commercial insurers have expanded coverage criteria, and Medicare coverage discussions are ongoing.

Compounded Tirzepatide Through Trimi

Trimi offers compounded tirzepatide starting at $125 per month — making this FDA-approved treatment accessible without the brand-name cost barrier. Compounded tirzepatide uses the same active pharmaceutical ingredient as Zepbound and is prepared in FDA-regulated 503A or 503B compounding pharmacies that follow Current Good Manufacturing Practice (CGMP) standards.

Getting started with Trimi is straightforward: complete an online intake form describing your medical history and current OSA diagnosis, consult with a licensed provider via telehealth, and receive your prescription shipped directly to your door. No in-person office visits are required. Learn more about how to choose a compounded GLP-1 provider and what to look for in terms of quality, safety, and pricing.

If you are currently comparing your options for online GLP-1 access, our guide to the best online weight loss clinics in 2026 includes a detailed breakdown of cost, support, and clinical quality across providers.

Working With Your Sleep Specialist

Starting tirzepatide for sleep apnea should ideally be a coordinated effort between the provider prescribing tirzepatide and the sleep medicine specialist managing your OSA. Here is a practical framework:

1. Confirm your OSA severity with a recent sleep study. If your last sleep study was more than 2–3 years ago or was done before significant weight change, a repeat study may give a more accurate baseline.
2. Continue CPAP during tirzepatide treatment. Do not discontinue CPAP on the basis of feeling better, reduced snoring, or improved energy. AHI can remain elevated even when subjective symptoms improve.
3. Schedule a repeat sleep study after 15–20% weight loss. This is the inflection point at which AHI improvements are most likely to reach clinical significance. Use CPAP data (if available through a device app) to identify trends.
4. Discuss CPAP step-down based on objective data. If AHI drops below 15 events per hour, a conversation about reducing CPAP pressure, transitioning to an oral appliance, or discontinuing CPAP is appropriate.
5. Plan long-term monitoring. If you achieve OSA remission and continue tirzepatide, schedule annual reassessments. If you ever plan to discontinue tirzepatide, recheck your sleep study within 6–12 months.

The Broader Landscape: GLP-1 Medications and Sleep Medicine

The Zepbound OSA approval is likely the beginning of a broader integration of GLP-1 pharmacotherapy into sleep medicine. Semaglutide (Wegovy, Ozempic) has shown similar but somewhat smaller effects on AHI in observational studies and is in late-stage clinical trials for an OSA indication. Next-generation triple agonists like retatrutide, which has shown weight loss of up to 24% in phase 2 trials, may produce even higher rates of OSA remission once the data matures.

For patients who have struggled with CPAP intolerance, failed oral appliance therapy, or want to address the root cause of their OSA rather than manage it nightly, tirzepatide now represents a clinically validated, FDA-approved alternative. For the millions of undiagnosed or undertreated OSA patients who have never been offered a pharmacological option, this approval opens an entirely new treatment conversation.

To compare tirzepatide directly with semaglutide across multiple health outcomes, see our detailed guide Tirzepatide vs Semaglutide: Which Is Right for You?.

Frequently Asked Questions

Conclusion

The FDA approval of Zepbound for obstructive sleep apnea is one of the most clinically significant developments in sleep medicine in decades. Backed by the SURMOUNT-OSA trials — which demonstrated 55–63% AHI reductions and nearly a 50% remission rate — tirzepatide offers something no treatment has before: a pharmacological approach that simultaneously treats OSA and reverses the obesity driving it.

For patients with obesity and moderate-to-severe OSA, the choice is no longer just between CPAP and surgery. A weekly injection starting at $125/month through Trimi can produce transformational changes in both sleep health and overall metabolic health. If you or someone you know has been diagnosed with — or suspects — obstructive sleep apnea, this approval is worth discussing with a qualified provider. Accessible, affordable GLP-1 care is now a real option for sleep apnea patients across the country.